Announcements Trials
Browse Landscape Eligibility

Clinical Trials

2 trials
RecentStart dateEnrollment
HA 22 × Clear all

Phase

Phase 2 1

Status

Terminated 1Approved for marketing 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

Cisplatin 3176Cyclophosphamide 3170Carboplatin 2955Radiotherapy 2772Paclitaxel 2705Gemcitabine 2549pembrolizumab 2368Bevacizumab 2191Docetaxel 2190Fluorouracil 1837Capecitabine 1815Oxaliplatin 1723Dexamethasone 1589Nivolumab 1575Doxorubicin 1500Rituximab 1480Magnetic Resonance Spectroscopy 1365Etoposide 1341Irinotecan 1240Leucovorin 1215Drug Therapy 1189Cytarabine 1125Pemetrexed 1067fludarabine 1035Specimen Handling 985Vincristine 962Cetuximab 938Prednisone 938Trastuzumab 936Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03501615 2020-06-29

MOXE

AstraZeneca

Approved for marketing
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT02338050 2015-09-16

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Center for International Blood and Marrow Transplant Research

Phase 2 Terminated
1 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡